At a Glance
| Indication | Cancer |
| Drug | Pembrolizumab |
| Mechanism of Action | Immune checkpoint inhibitor |
| Company | Orion Pharma |
| Category | Corporate & Strategic |
| Sub Category | Licensing Agreement |
| Therapeutic Area | Oncology |
| Licensed Territory | Europe |
| Deal Type | Commercialization Agreement |
| Product Type | Biosimilar |
| Distribution Rights | Exclusive distribution, marketing, and sales rights |
| Supplier Company | Qilu Pharma Europe |
| Recipient Company | Orion Pharma |
| Financial Terms | Revenue share, Milestone payments |
| Product Administration | Intravenous (IV) |
Orion Pharma Secures European Rights for Pembrolizumab Biosimilar
Orion Pharma and Qilu Pharma Europe have entered into an agreement for the commercialization of Qilu's intravenous (IV) pembrolizumab biosimilar product in Europe. Under the terms, Orion Pharma gains exclusive rights for distribution, marketing, and sales of the biosimilar across Europe. Qilu will supply the product and is entitled to a share of the revenue, along with specific milestone payments tied to the product's development, approval, and sales. This partnership aims to expand Orion's strategic goals and make affordable, high-quality medicines accessible.
- Orion Pharma has expanded its strategic partnership with Qilu Pharma Europe, securing exclusive rights for the commercialization of an IV pembrolizumab biosimilar in Europe. This move aligns with Orion's long-term objectives to enhance its portfolio and provide access to affordable, high-quality medicines.
- The agreement grants Orion Pharma exclusive rights for the distribution, marketing, and sales of Qilu's pembrolizumab biosimilar across the European market. Qilu Pharma Europe will be responsible for supplying the product to Orion Pharma.
- Qilu Pharma Europe is set to receive a share of the revenue generated from the biosimilar's sales in Europe. Additionally, the agreement includes provisions for certain milestone payments to Qilu, contingent upon the product's development, regulatory approval, and sales performance.
Frequently Asked Questions
Can you beat stage 4 cancer?
While stage 4 cancer is generally considered advanced and often incurable, the possibility of long-term survival or remission varies significantly. Outcomes depend heavily on the specific cancer type, the extent and location of metastases, and individual response to treatment. Advances in targeted therapies, immunotherapies, and precision medicine have improved prognosis for some patients, enabling prolonged disease control and even cure in rare cases.
What is the life expectancy of someone on KEYTRUDA?
There is no single life expectancy for individuals receiving KEYTRUDA, as outcomes are highly dependent on the specific cancer type and stage, prior therapies, patient's overall health, and individual response to treatment. KEYTRUDA is indicated across numerous malignancies, from adjuvant settings where it may contribute to long-term remission, to advanced metastatic diseases where it aims to extend overall survival and progression-free survival. Survival data are reported in clinical trials specific to each indication, showing varying median overall survival benefits compared to standard of care, but these are population averages and individual prognoses vary widely.
What stage of cancer is KEYTRUDA used for?
KEYTRUDA (pembrolizumab) is approved for a wide range of cancer stages, from early-stage adjuvant settings to advanced, unresectable, or metastatic disease. For instance, it is indicated as adjuvant therapy for certain Stage IB, II, and IIIA non-small cell lung cancer, Stage IIB, IIC, and III melanoma, and intermediate-high or high-risk renal cell carcinoma. It is also extensively used for locally advanced, recurrent, or metastatic disease across numerous cancer types, including melanoma, NSCLC, head and neck squamous cell carcinoma, and triple-negative breast cancer. Additionally, it holds a tumor-agnostic indication for unresectable or metastatic MSI-H/dMMR solid tumors.
What is the life expectancy for someone with stage 4 cancer after stopping chemotherapy?
Life expectancy for stage 4 cancer patients after stopping chemotherapy is highly variable and cannot be generalized. Prognosis is critically dependent on the specific cancer type, extent of metastatic disease, prior response to therapy, and the reason for discontinuation. The patient's performance status and the availability of subsequent palliative or supportive care also significantly influence outcomes. While often measured in months, individual survival times vary widely based on these complex clinical parameters.
How successful are clinical trials for cancer?
Clinical trials for cancer have a low success rate, with only about 3-7% of oncology drugs progressing from Phase 1 to regulatory approval. This is significantly lower than the average for all therapeutic areas, reflecting the inherent complexities of cancer biology and the high bar for efficacy and safety. Attrition is particularly high during the transition from Phase 2 to Phase 3, where many promising candidates fail to demonstrate sufficient benefit or acceptable toxicity profiles.
What is the 62 day rule for cancer?
The 62-day rule is a key waiting time target within the NHS in England, stipulating that patients referred urgently with suspected cancer should begin their first definitive treatment within 62 days of the referral. This target applies to patients referred by a GP, screened positive for cancer, or transferred from another consultant with suspected cancer. Its purpose is to ensure prompt diagnosis and initiation of treatment, aiming to improve patient outcomes by reducing delays.
What are the latest findings in cancer research?
Recent cancer research highlights the development of novel targeted therapies addressing previously challenging mutations like KRAS G12C, expanding treatment options for non-small cell lung cancer and other solid tumors. Immunotherapy continues to evolve with advancements in bispecific antibodies and CAR T-cell therapies showing promise in solid tumor settings, alongside refined biomarker strategies for patient selection. Furthermore, multi-cancer early detection (MCED) tests utilizing circulating tumor DNA are progressing, aiming to improve diagnostic precision and intervention timelines.
What is the new miracle drug for cancer?
There is no single "miracle drug" that universally cures all cancers. However, significant advancements continue in oncology, particularly with targeted therapies, immunotherapies, and cell-based treatments, which offer improved outcomes for specific cancer types and patient populations. Research focuses on personalized medicine approaches to enhance efficacy and minimize toxicity.
Contact Us
📍
Address
350 Springfield Avenue,
Suite #200 Summit, NJ 07901
✉️
For General Inquiry
info@pienomial.com
